Table 1 Clinicopathological characteristics of all diffuse glioma cases in relation to CDKN2A homozygous deletion status.

From: Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma

 

N (%)

 

All

CDKN2A HD

CDKN2A non-HD

Number

178

 

78

(43.8)

100

 (56.2)

Age at diagnosis

  Median (y)

49.0

61.0

41.5

  Range (y)

17–87

29–87

17–85

Sex

  Male

99

(55.6)

47

(26.4)

52

(29.2)

  Female

79

(44.4)

31

(17.4)

48

(27.0)

Group

 IDH-mutant astroa

77

 

17

(22.1)

60

(77.9)

  WHO grade II

 

15 (19.5)

 

0 (0.0)

 

15 (19.5)

 WHO grade III

 

35 (45.5)

 

4 (5.2)

 

31 (40.3)

  WHO grade IV

 

27 (35.1)

 

13 (16.9)

 

14 (18.2)

 IDH-mutant oligob

13

 

6

(46.2)

7

(53.8)

  WHO grade II

 

5 (38.5)

 

1 (7.7)

 

4 (30.8)

  WHO grade III

 

8 (61.5)

 

5 (38.5)

 

3 (23.1)

 IDH-wildtype

88

 

55

(62.5)

33

(37.5)

  1. aIDH-mutant astro; IDH-mutant astrocytoma.
  2. bIDH-mutant oligo; IDH-mutant oligodendroglioma.
Back to article page